CNBC   |  April 02, 2014

FDA panel backs Mannkind's 'Afrezza'

Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel to approve his company's inhaled insulin treatment "Afrezza."

Share This:

Sorry, we do not have a transcript available for this video at this time.